12.03
Evolus Inc stock is traded at $12.03, with a volume of 534.67K.
It is down -0.17% in the last 24 hours and down -17.55% over the past month.
See More
Previous Close:
$12.05
Open:
$11.7
24h Volume:
534.67K
Relative Volume:
0.71
Market Cap:
$778.30M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-11.14
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
-7.46%
1M Performance:
-17.55%
6M Performance:
-25.74%
1Y Performance:
-14.07%
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
EOLS
Evolus Inc
|
12.03 | 778.30M | 202.09M | -61.69M | -35.64M | -1.08 |
![]()
ZTS
Zoetis Inc
|
164.65 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.87 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
10.29 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.37 | 17.71B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
308.27 | 14.37B | 2.76B | 1.11B | 898.10M | 22.77 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
Jun-23-22 | Initiated | Needham | Buy |
May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
Jan-20-22 | Upgrade | Truist | Hold → Buy |
May-06-21 | Upgrade | Mizuho | Neutral → Buy |
Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
Feb-24-21 | Downgrade | Truist | Buy → Hold |
Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
Feb-06-20 | Resumed | Mizuho | Buy |
Nov-26-19 | Initiated | SVB Leerink | Outperform |
Sep-05-19 | Resumed | Mizuho | Buy |
Jun-28-19 | Initiated | Wells Fargo | Market Perform |
Jun-11-19 | Initiated | Barclays | Underweight |
Mar-20-19 | Initiated | SunTrust | Buy |
Feb-14-19 | Initiated | H.C. Wainwright | Buy |
Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Evolus CEO David Moatazedi sells $77,512 in stock By Investing.com - Investing.com Australia
Evolus CEO David Moatazedi sells $77,512 in stock - Investing.com India
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference - BioSpace
Evolus Inc (EOLS) Shares Down 4.54% on Mar 25 - GuruFocus
Evolus Leadership Reveals Growth Strategy at Major Healthcare Conference - Stock Titan
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 21, 2025 - BioSpace
Investing in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gain - Yahoo Finance
Evolus reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:17 pm EDT - MarketScreener
Evolus director David Moatazedi sells $1.37 million in stock By Investing.com - Investing.com Australia
Evolus Growth Continues: 14 New Employees Join as Company Strengthens Talent Pool - Stock Titan
Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference - Business Wire
Evolus executive Avelar Rui sells $369,867 in stock By Investing.com - Investing.com South Africa
Evolus CFO Sandra Beaver sells $119,242 in company stock By Investing.com - Investing.com South Africa
Evolus chief marketing officer sells $60,124 in common stock By Investing.com - Investing.com South Africa
Evolus CFO Sandra Beaver sells $119,242 in company stock - Investing.com
Evolus executive Avelar Rui sells $369,867 in stock - Investing.com India
Evolus director David Moatazedi sells $1.37 million in stock - Investing.com India
Evolus chief marketing officer sells $60,124 in common stock - Investing.com
When the Price of (EOLS) Talks, People Listen - news.stocktradersdaily.com
Evolus Executives Sell Shares to Cover Tax Obligations - TradingView
Trade Alert: Independent Director Of Evolus Karah Parschauer Has Sold Stock - Simply Wall St
Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting - Business Wire
Evolus director Parschauer sells $167,465 in common stock - Investing.com India
Evolus director Parschauer sells $167,465 in common stock By Investing.com - Investing.com South Africa
Evolus’s SWOT analysis: fda approval boosts stock as dermal filler market expands - Investing.com India
Evolus’s SWOT analysis: fda approval boosts stock as dermal filler market expands By Investing.com - Investing.com South Africa
Evolus at Barclays Conference: Strategic Growth and New Launch - Investing.com
Evolus at Leerink’s Global Healthcare Conference: Strategic Growth Insights - Investing.com India
Evolus at Leerink’s Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas - The Motley Fool
What is HC Wainwright’s Estimate for Evolus FY2025 Earnings? - Defense World
(EOLS) Investment Analysis - Stock Traders Daily
Evolus, Inc.: Navigating Financial Challenges Amidst Ongoing Losses and Market Uncertainty - MSN
Global Jeuveau Market Outlook 2025-2034: Growth Drivers, Share, And Trends - EIN News
Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Principal Financial Group Inc. - Defense World
Evolus, Inc. to Host Earnings Call - ACCESS Newswire
Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Rhumbline Advisers - Defense World
IFP Advisors Inc Has $52,000 Position in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus’s Strong Market Position and Growth Potential Highlighted by Robust Revenues and Strategic Expansions - TipRanks
HC Wainwright Reaffirms “Buy” Rating for Evolus (NASDAQ:EOLS) - Defense World
Evolus’s Promising Growth and Strategic Positioning Earns a ‘Buy’ Rating from Analyst Douglas Tsao - TipRanks
Evolus, Inc. Earnings Call Highlights Robust Growth and Profitability - TipRanks
Evolus Inc Reports Q4 2024 Revenue of $79 Million, Surpassing Es - GuruFocus.com
Stifel maintains Buy on Evolus stock, sets $25 target By Investing.com - Investing.com UK
H.C. Wainwright maintains Buy rating on Evolus stock at $27 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Evolus stock at $27 target - Investing.com
Evolus Celebrates Strong Demand For Jeuveau Wrinkle Treatment - Finimize
Assessing Evolus: Insights From 6 Financial Analysts - Benzinga
Evolus price target raised to $25 from $22 at Barclays - TipRanks
Evolus reports Q4 EPS (11c) vs (21c) last year - TipRanks
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):